Healthcare Aug 30, 2021 01:46 PM (GMT+8) · EqualOcean
Financial Associated Press, August 30 - on August 30, the official website of the State Food and drug administration showed that the anti-PD-1 whole person innovative antibody drug cyprimab (gls-010) jointly developed by Yuheng pharmaceutical / Yaoming biology has been approved by nmpa to be listed for the treatment of patients with recurrent or refractory classic Hodgkin's lymphoma (R / R CHL) above the second line. This is the sixth domestic PD-1 mAb approved by nmpa.
Related companies: